In neonates, pharmacogenetics has an additional layer of complexity. This is because in
addition to genetic variability in genes that code for proteins relevant to clinical …

Purpose Personalized pharmacotherapy, including for the pediatric population, provides
optimal treatment and has emerged as a major trend owing to advanced drug therapeutics …

In a 2010 review in Clinical Pharmacology & Therapeutics, Nick Holford noted that in
neonates and young infants, maturation of the organs responsible for drug clearance is a …

Identification of markers involved in drug disposition is crucial for drugs with a narrow
therapeutic index. Individual genomic differences can affect the pharmacology of some …

The concept of precision or personalized medicine in pediatrics is still in its infancy, and it is
difficult to conduct clinical studies in pediatrics to acquire meaningful correlations between …

As the activity of certain drug metabolizing enzymes or transporter proteins can vary with
age, the effect of ontogenetic and genetic variation on the activity of these enzymes is critical …

The advances in high-throughput genomic technologies have improved the understanding
of disease pathophysiology and have allowed a better characterization of drug response …

The goal of pharmacogenomics is to comprehend the effect of inter-individual genetic
variations on the outcome of treatment.[1, 2] By understanding the role that these genetic …

A major challenge for clinicians, pharmaceutical companies and regulatory agencies is to
better understand the relative contributions of ontogeny and genetic variation to observed …

Interindividual variability in the disposition and action associated with similar doses of a
given medication is an inherent characteristic of both adult and pediatric populations …